Enanta製藥 ENTA 深 滬
等待開盤 01-13 09:30:00 美东时间
12.91
-0.200
-1.53%
華盛通- 最 高13.14
- 今 開13.06
- 成交量 30.34万股
- 最 低 12.53
- 昨 收 13.11
- 總市值 3.72亿
- 52周最高 17.15
- 市盈率 靜 --
- 換手率 1.05%
- 52周最低 4.09
- 委 比 -97.67%
- 總股本 2885.29万
- 歷史最高 127.77
- 量 比 1.15
- 振 幅 4.65%
- 歷史最低 4.09
- 每 手 1
- 風險率 3.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Enanta Pharmaceuticals (ENTA) Receives a Buy from H.C. Wainwright
In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Bu...
01-09 19:36
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.
01-09 19:32
Enanta Pharmaceuticals Reports Progress in Drug Development
Enanta Pharmaceuticals ( ($ENTA) ) has released its Q4 earnings. Here is a brea...
2025-11-18 12:02
Enanta Pharma Q4 EPS $(0.87) Beats $(1.03) Estimate, Sales $15.125M Miss $15.956M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.03) by 15.29 percent. This is a 36.03 percent increase over losses of $(1.36) per share from the
2025-11-18 05:02
Earnings Scheduled For November 17, 2025
Companies Reporting Before The Bell • So-Young Intl (NASDAQ:SY) is projected to...
2025-11-17 19:11
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy
Shares of Enanta Pharmaceuticals traded higher on Friday after two straight sessions of losses as J.P. Morgan launched its coverage with an Overweight recommendation, citing the potential of zelicapav...
2025-11-15 00:54
JP Morgan Initiates Coverage On Enanta Pharma with Overweight Rating, Announces Price Target of $17
JP Morgan analyst Anupam Rama initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Overweight rating and announces Price Target of $17.
2025-11-14 20:28
W. P. Carey Announces Third Quarter 2025 Financial Results
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- W. P. Carey Inc. (NYSE: WPC) (W. P. Carey or the Company), a net lease real estate investment trust, today reported its financial results for the thir...
2025-10-29 04:05
